wire - news in brief
Category
Results 51 - 100 of 348.
Federal Councillor Ignazio Cassis, Head of the Federal Department of Foreign Affairs (FDFA), announced on Tuesday Switzerland's support for EPFL's project to create a "Transnational Red Sea Research Center".
FDA approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC
For his thesis at EPFL, Fernando Simas studied how cable cars could be an appealing transportation option for city commuters, and how they could be incorporated into tomorrow's urban landscapes.
In the Mesorhabditis belari roundworm, the sole purpose of males is to help females produce clones of themselves. This unique form of reproduction was recently described by an international research team with participation of Peter Meister from the Institute of Cell Biology of the University of Bern.
New SNSF Sinergia Research Consortium: The Swiss Elites Observatory recruits !
The Universities of Lausanne, Fribourg and Zurich launch in September 2019 a new ‘Sinergia' research consortium entitled ‘Local power structures and transnational connections.
The Universities of Lausanne, Fribourg and Zurich launch in September 2019 a new ‘Sinergia' research consortium entitled ‘Local power structures and transnational connections.
EPFL encourages its researchers to publish in open-access journals
EPFL has adopted an Open Access Policy clearly setting out its position on open access to EPFL publications.
EPFL has adopted an Open Access Policy clearly setting out its position on open access to EPFL publications.
European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease
MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease
MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
Study is planned to assess efficacy and safety of Entresto (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019 C
Study is planned to assess efficacy and safety of Entresto (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019 C
Bernese Mars camera CaSSIS returns spectacular images
Three years ago, on 14 March 2016, the Bernese Mars camera CaSSIS started its journey to Mars with the "ExoMars Trace Gas Orbiter" spacecraft.
Three years ago, on 14 March 2016, the Bernese Mars camera CaSSIS started its journey to Mars with the "ExoMars Trace Gas Orbiter" spacecraft.
In a large-scale, Europe-wide drug monitoring project, the wastewater of around 38 million people in 85 cities was analysed in the spring.
European Commission approves Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison Only prophylactic medicine that can be given subcutaneously
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison Only prophylactic medicine that can be given subcutaneously
New Marie Curie and EMBO Fellows at the FMI
Five of our postdocs were recently awarded the prestigious EMBO and Maria Sklodowska-Curie Actions (MSCA) Fellowships.
Five of our postdocs were recently awarded the prestigious EMBO and Maria Sklodowska-Curie Actions (MSCA) Fellowships.
Empa is presenting sustainable fuels of the future at the Petroleum Association's stand in Hall 6 of the Geneva Motor Show.
Empa is presenting sustainable fuels of the future at the Petroleum Association's stand in Hall 6 of the Geneva Motor Show.
EPFL software mines rich medical data while keeping it secure
MedCo , developed in the lab of EPFL professor Jean-Pierre Hubaux in collaboration with professor Bryan Ford 's DEDIS lab and the Lausanne University Hospital ( CHUV ), is the first operational system to protect sensitive patient data - including genetic information - so that it can be used collectively for crucial medical research.
MedCo , developed in the lab of EPFL professor Jean-Pierre Hubaux in collaboration with professor Bryan Ford 's DEDIS lab and the Lausanne University Hospital ( CHUV ), is the first operational system to protect sensitive patient data - including genetic information - so that it can be used collectively for crucial medical research.
The latest urine-diverting toilet is being "officially" presented today at the ISH sanitation trade fair in Frankfurt.
EPFL has become the coordinator of Be-Smart, an EU research project that aims to step up the deployment of building-integrated photovoltaics (BIPV) and cut their costs by 75% between now and 2030.
FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need Roche today announ
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need Roche today announ
Roche’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer Each year about 300,000 women are diag
PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer Each year about 300,000 women are diag
European Commission approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (N
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (N
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.
Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submiss
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submiss
A look into the future
What could the "gas station of the future" look like? What services does it offer? Which fuels can be filled up there and where do they come from? The Swiss Oil Industry Association (Erdöl-Vereinigun
What could the "gas station of the future" look like? What services does it offer? Which fuels can be filled up there and where do they come from? The Swiss Oil Industry Association (Erdöl-Vereinigun
Judit Leinert, you're a specialist in good decision making. How can I decide on the perfect place to go on holiday this summer? In my research group, we approach decision making with the help of "Multi-Criteria Decision Analysis", or MCDA.
Novartis Cosentyx shows superior improvements in psoriasis patients’ quality of life versus Janssen’s IL-23 Stelara *
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara * (68.4% versus 55.9%, respectively) Results from CLARITY study presented in 2018 showed Cosentyx was significantly more effective than Stelara * in delivering clear and almost clear skin at 12 and 16 weeks.
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara * (68.4% versus 55.9%, respectively) Results from CLARITY study presented in 2018 showed Cosentyx was significantly more effective than Stelara * in delivering clear and almost clear skin at 12 and 16 weeks.
The European Commission has chosen Time Machine as one of the six proposals retained for preparing large scale research initiatives to be strategically developed in the next decade.
FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta? (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta? (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment